WuXi PharmaTech (NYSE: WX) Fills Three Senior Level Positions

WuXi PharmaTech (NYSE: WX) Fills Three Senior Level Positions

August 13, 2007

    SHANGHAI, China, Aug. 13 /Xinhua-PRNewswire/ -- WuXi
PharmaTech (NYSE: WX), China's premier provider of
pharmaceutical R&D outsourcing services announced today
the addition of three key senior level positions. These
positions include Executive Vice President of Operations,
Vice President of Toxicology and Vice President of Finance.

    (Logo: http://www.xprn.com.cn/xprn/sa/200611271812.jpg
)

    Mr. Edward Hu will serve as WuXi PharmaTech's Executive
Vice President of Operations, reporting directly to Dr. Ge
Li, Chairman and Chief Executive Officer of the company.
Mr. Hu brings an extensive experience in operations and
financial management. Before his appointment with WuXi
PharmaTech, Mr. Hu was the Senior Vice President and Chief
Operating Officer of Tanox, Inc. (Nasdaq listed company)
where he managed operations, finance, IT, project
management and strategic planning. Tanox was recently
acquired by Genentech, Inc. In addition to his experience
with Tanox, Inc., Mr. Hu has held management positions at
Biogen Idec and Merck. Mr. Hu received his MBA and MS in
Chemistry from Carnegie Mellon University, Pittsburgh,
Pennsylvania.

    Dr. Victor H. Chen will serve as Vice President and
Head of Toxicology, SuZhou PharmaTech, reporting directly
to Dr. Ge Li, Chairman and Chief Executive Officer of the
company. Dr. Chen will work closely with Dr. Lijie Fu, Head
of Operation, SuZhou PharmaTech to further enhance WuXi's
capability and capacity in Toxicology services. Prior to
joining WuXi PharmaTech, Dr. Chen held the director
position of Toxicology for ImClone Systems Inc. (NASDAQ:
IMCL). In addition, Dr. Chen previously held positions in
Pfizer and Bristol-Myers Squibb as well as University of
Hawaii. Dr. Chen earned his Ph.D. in Environmental
Toxicology from the University of California, Riverside and
is a Diplomat of American Board of Toxicology.

    Reporting to Mr. Benson Tsang, Chief Financial Officer
of the company, Christine Lu-Wong, WuXi PharmaTech's newly
appointed VP of Finance, has years of experience with
"Big Four" in auditing, finance and accounting.
She held various finance positions at multi-national
companies such as Hewlett-Packard and Sun Microsystems.
Prior to joining WuXi PharmaTech, she consulted many
companies in San Jose, California including Google and
Altera Corporation.  Ms. Lu-Wong received her MBA in
Accounting from Golden Gate University, California, and is
a U.S. Certified Public Accountant.

    "I am delighted to welcome Ed, Victor and
Christine to our senior management team.  Strong execution
and relentless focus on delivering quality services have
been critical in our success in providing high quality
services and expanding service offerings to our clients. As
we continue to strengthen and broaden our service portfolio,
we must further improve our operation at all levels.
Development of significant pre-clinical and biology
capabilities and further strengthening our financial
management and internal control system are our priorities.
I am very confident that by leveraging our past operation
experiences and success in chemistry services these three
executives will help augment our service capability and
capacity to create more values for our customers and
shareholders", commented Dr. Ge Li, Chairman and Chief
Executive Officer of WuXi PharmaTech.

    About WuXi PharmaTech Co., Ltd.

    Founded in 2000, Shanghai-based WuXi PharmaTech is the
leading China-based pharmaceutical and biotechnology
R&D outsourcing company. As a research- driven and
customer-focused company, WuXi PharmaTech provides
pharmaceutical and biotechnology companies a broad and
integrated portfolio of laboratory and manufacturing
services throughout the drug discovery and development
process. WuXi PharmaTech's services are designed to assist
its global partners in shortening the cycle and lowering
the cost of drug discovery and development by providing
cost-effective and efficient outsourcing solutions that
save its customers both time and money. Its operations are
grouped into two segments: laboratory services, consisting
of discovery chemistry, service biology, analytical,
pharmaceutical development and process development
services, and manufacturing, focusing on manufacturing of
advanced intermediates and active pharmaceutical
ingredients for R&D use. In 2006, WuXi PharmaTech
provided services to 70 pharmaceutical and biotechnology
customers, including nine of the top 10 pharmaceutical
companies in the world, as measured by 2006 total revenues.
For more information, please visit:
http://www.wuxipharmatech.com .






    For more information, please contact:
   
     Sherry Shao
     Tel:   [phone]
     Email: [e-mail]